

Appl. No. 10/666,689
Amend. dated April 14, 2006
Response to Office Action mailed on: October 14, 2005

Patent Docket P0706P2C2D2C1
Express Mail No. EV384508739 US

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-19 (Cancelled).

20. (Previously presented) An isolated polypeptide comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) having from 0 to 5 amino acid residues that are added, deleted or conservatively substituted.

21. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that added.

22. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are deleted.

23. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) with from 0 to 5 amino acid residues that are conservatively substituted.

24. (Previously presented) The polypeptide of Claim 20 comprising the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6).

25. (Presently amended) An isolated polypeptide comprising an extracellular regionsegment of the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6).

Appl. No. 10/666,689
Amend. dated April 14, 2006
Response to Office Action mailed on: October 14, 2005

Patent Docket P0706P2C2D2C1
Express Mail No. EV384508739 US

26. (Previously presented) The polypeptide of Claim 25, wherein the extracellular region comprises at least 10 contiguous residues.
27. (Presently amended) The polypeptide of Claim 25, wherein the extracellular region segment comprises the N-terminal fragment.
28. (Previously presented) The polypeptide of Claim 27, wherein the N-terminal extracellular region comprises at least 10 contiguous residues.
29. (Previously presented) A composition comprising the polypeptide of Claim 20 and a pharmaceutically acceptable carrier.
30. (Previously presented) A composition comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.
31. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 20.
32. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 21.
33. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 22.
34. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 23.

Appl. No. 10/666,689
Amend. dated April 14, 2006
Response to Office Action mailed on: October 14, 2005

Patent Docket P0706P2C2D2C1
Express Mail No. EV384508739 US

35. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 24.
36. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 25.
37. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 26.
38. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 27.
39. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR polypeptide of Claim 28.
40. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the PF4AR amino acid sequence of Figure 5 (SEQ ID NO:6) having from 0 to 5 amino acid residues that are added, deleted or conservatively substituted.
41. (Withdrawn-Previously presented) The nucleic acid molecule of Claim 40 operably linked to a promoter.
42. (Withdrawn-Previously presented) An expression vector comprising the nucleic acid molecule of Claim 41 operably linked to control sequences recognized by a host cell transformed with the vector.
43. (Withdrawn-Previously presented) A host cell transformed with the vector of Claim 42.

44. (Withdrawn-Previously presented) A method of using the nucleic acid of Claim 40, comprising culturing a host cell that has been transformed with a vector comprising the nucleic acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide.
45. (Withdrawn-Previously presented) The method of Claim 44 further comprising recovering the polypeptide from the host cell.
46. (Withdrawn-Previously presented) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding at least 10 contiguous amino acid residues from an extracellular domain of the PF4AR polypeptide of Figure 5 (SEQ ID NO:6).
47. (Withdrawn-Previously presented) The nucleic acid molecule of Claim 46, wherein the encoded polypeptide is an N-terminal extracellular domain.
48. (Withdrawn-Previously presented) The nucleic acid molecule of Claim 46 operably linked to a promoter.
49. (Withdrawn-Previously presented) An expression vector comprising the nucleic acid molecule of Claim 48 operably linked to control sequences recognized by a host cell transformed with the vector.
50. (Withdrawn-Previously presented) A host cell transformed with the vector of Claim 49.
51. (Withdrawn-Previously presented) A method of using the nucleic acid of Claim 46, comprising culturing a host cell that has been transformed with a vector comprising the nucleic

acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide.

52. (Withdrawn-Previously presented) The method of Claim 51 further comprising recovering the polypeptide from the host cell.

53. (Withdrawn-Previously presented) A method for determining the presence or absence of a PF4AR nucleic acid in a sample, comprising the steps of:

- (a) selecting a probe comprising at least 20 contiguous nucleotides from the nucleic acid sequence of Figure 5 (SEQ ID NO:5);
- (b) hybridizing the probe to any PF4AR nucleic acid present in the sample to form a probe/PF4AR nucleic acid complex;
- (c) detecting the presence or absence of the probe/PF4AR nucleic acid complex in the sample, and
- (d) determining the presence or absence of PF4AR nucleic acid in the sample based on the result of step (c).

54. (Withdrawn-Previously presented) A method of amplifying a PF4AR nucleic acid in sample, comprising the steps of:

- (a) selecting an oligonucleotide primer having a 3' terminus consisting of at least 20 contiguous nucleotides selected from the nucleic acid sequence of Figure 5 (SEQ ID NO:5) or at least 20 contiguous nucleotides complementary to said primer;
- (b) hybridizing the oligonucleotide primer to a single strand of the PF4AR nucleic acid in the sample, and
- (c) performing a nucleic acid polymerase reaction wherein the hybridized oligonucleotide primer primes the synthesis of a second strand complementary to the single stranded nucleic acid to form an amplified nucleic acid.

Appl. No. 10/666,689
Amend. dated April 14, 2006
Response to Office Action mailed on: October 14, 2005

Patent Docket P0706P2C2D2C1
Express Mail No. EV384508739 US

55. (Withdrawn-Previously presented) An antibody capable of binding to the PF4AR polypeptide of Figure 5 (SEQ ID NO:6) and that does not cross-react with other PF4AR polypeptides.
56. (Withdrawn-Previously presented) The antibody of Claim 55, which is a polyclonal antibody.
57. (Withdrawn-Previously presented) The antibody of Claim 55, which is a monoclonal antibody.
58. (Withdrawn-Previously presented) The antibody of Claim 55, which is an IgG1 isotype antibody.
59. (Withdrawn-Previously presented) An antibody capable of binding an extracellular region of the PF4AR polypeptide of Figure 5 (SEQ ID NO:6).
60. (Withdrawn-Previously presented) The antibody of Claim 59, wherein the extracellular region is an N-terminal extracellular region.
61. (Withdrawn-Previously presented) The antibody of Claim 59, wherein the extracellular region comprises at least 10 contiguous amino acid residues of Figure 5 (SEQ ID NO:6).
62. (Withdrawn-Previously presented) The antibody of Claim 59, which is a polyclonal antibody.

Appl. No. 10/666,689
Amend. dated April 14, 2006
Response to Office Action mailed on: October 14, 2005

Patent Docket P0706P2C2D2C1
Express Mail No. EV384508739 US

63. (Withdrawn-Previously presented) The antibody of Claim 59, which is a monoclonal antibody.

64. (Withdrawn-Previously presented) The antibody of Claim 59, which is an IgG1 isotype antibody.

65. (Withdrawn-Previously presented) The antibody of Claim 60, which is a monoclonal antibody.

66. (Withdrawn-Previously presented) The antibody of Claim 60, which is an IgG1 isotype antibody.

67. (Withdrawn-Previously presented) The antibody of Claim 61, which is a monoclonal antibody.

68. (Withdrawn-Previously presented) The antibody of Claim 61, which is an IgG1 isotype antibody.

69. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 55 and a pharmaceutically acceptable carrier.

70. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 59 and a pharmaceutically acceptable carrier.

71. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 63 and a pharmaceutically acceptable carrier.

Appl. No. 10/666,689
Amend. dated April 14, 2006
Response to Office Action mailed on: October 14, 2005

Patent Docket P0706P2C2D2C1
Express Mail No. EV384508739 US

72. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 65 and a pharmaceutically acceptable carrier.

73. (Withdrawn-Previously presented) A composition comprising the antibody of Claim 67 and a pharmaceutically acceptable carrier.